SIRS-Lab, Pfizer Target Sepsis with MDx Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm SIRS-Lab today announced a collaboration with Pfizer Pharma focused on sepsis diagnostics and treatment.

The firms will initially evaluate the clinical impact of using molecular-based tests for diagnosis of severe fungal blood stream infections, as well as the pharmacoeconomics of such an approach.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.